I measured every product Amazon sells for "baby lotion", "baby oil" and "baby cream" in India. The shelf is worth ₹97.9 crore a year, and Indian D2C brands hold 9.8% of it.
A fortnight ago I posted a measurement of the Indian serum shelf: 13 D2C brands, ₹159 crore a year on Amazon. That shelf belongs to Indian D2C almost entirely.
So I assumed baby skincare would look similar. Same buyer, adjacent aisle, and every D2C brand in the country seems to have a baby range now.
It does not look similar at all.
I took three searches Amazon actually merchandises, baby lotion, baby massage oil and baby cream, three pages each, and harvested 421 distinct organic products. I then opened the 80 highest-revenue ones individually to confirm each brand from Amazon's own "Visit the … Store" link and read the MRP and the price per 100ml, which search pages do not publish. Those 80 products are 92.5% of the measured revenue.
Here is what came back.
The shelf is worth ₹97.9 crore a year. Indian D2C has 9.8% of it.
| Who owns it | Brands | ₹cr/yr | Share |
|---|---|---|---|
| Dermatology / pharma | 4 | 47.1 | 48.0% |
| Multinational consumer | 5 | 24.2 | 24.7% |
| Indian large-cap & gear | 5 | 14.1 | 14.4% |
| Indian D2C | 7 | 9.6 | 9.8% |
| Unclassified | 4 | 3.1 | 3.1% |
| Total | 25 | 97.9 | 100% |
Cetaphil, Aveeno and Sebamed take 58.5% between them. Add Atogla and Venusia, both pharmaceutical brands (Torrent and Dr. Reddy's), and dermatology alone is 48%.
Mamaearth, the largest listed D2C beauty company in India, holds 0.8% of this shelf.
The full shelf
Indian D2C brands in bold.
| # | Brand | Owner | ₹cr/yr | Units/mo | Med. disc | ₹/100ml | Rating |
|---|---|---|---|---|---|---|---|
| 1 | Cetaphil | pharma | 21.44 | 24,400 | 10% | 332 | 4.44 |
| 2 | Aveeno | MNC | 20.04 | 18,300 | 23% | 456 | 4.46 |
| 3 | Sebamed | pharma | 15.77 | 25,400 | 16% | 502 | 4.49 |
| 4 | Himalaya | Indian | 9.83 | 25,600 | 26% | 82 | 4.36 |
| 5 | ATOGLA | pharma | 7.21 | 9,000 | 4% | 304 | 4.50 |
| 6 | Mamansh | Indian D2C | 3.32 | 5,900 | 20% | 199 | 4.33 |
| 7 | VENUSIA | pharma | 2.64 | 4,000 | 12% | 285 | 4.45 |
| 8 | Parachute Advansed | Indian | 2.50 | 7,000 | 26% | 90 | 4.33 |
| 9 | B4 Nappi Cream | unclassified | 1.78 | 5,000 | 4% | 396 | 4.50 |
| 10 | Mother Sparsh | Indian D2C | 1.74 | 5,900 | 46% | 68 | 4.30 |
| 11 | Johnson's Baby | MNC | 1.66 | 5,000 | 40% | 80 | 4.40 |
| 12 | Baby Forest | Indian D2C | 1.57 | 1,600 | 8% | 460 | 4.45 |
| 13 | Mustela | MNC | 1.24 | 1,300 | 29% | 500 | 4.50 |
| 14 | Baby Dove | MNC | 0.92 | 4,000 | 45% | 48 | 4.40 |
| 15 | Little Rituals | Indian D2C | 0.92 | 1,200 | 20% | 369 | 4.60 |
| 16 | TuCo | Indian D2C | 0.85 | 3,000 | 19% | 250 | 4.15 |
| 17 | Mamaearth | Indian D2C | 0.78 | 1,900 | 23% | 85 | 4.25 |
| 18 | Dabur | Indian | 0.72 | 1,800 | 20% | 116 | 4.35 |
| 19 | LuvLap | Indian | 0.71 | 3,000 | 55% | 28 | 4.30 |
| 20 | Eight Roots | unclassified | 0.54 | 500 | 10% | 899 | 4.20 |
| 21 | Figaro Baby | unclassified | 0.52 | 2,000 | 42% | 108 | 4.30 |
| 22 | Root and Soil | Indian D2C | 0.39 | 900 | 3% | 1436 | 4.60 |
| 23 | Mee Mee | Indian | 0.31 | 1,000 | 26% | 64 | 4.30 |
| 24 | Chicco | MNC | 0.30 | 1,000 | 16% | 126 | 4.40 |
| 25 | Daffy | unclassified | 0.24 | 400 | 17% | 250 | 4.50 |
The number that explains the shelf
Look at rows 3 and 4.
| Brand | Units/mo | ₹/100ml | ₹cr/yr |
|---|---|---|---|
| Himalaya | 25,600 | 82 | 9.83 |
| Sebamed | 25,400 | 502 | 15.77 |
Almost identical volume. Six times the price per unit. Sebamed earns 60% more revenue from 200 fewer units a month.
That is not a pricing accident, it is the whole category in one comparison. On a shelf where the buyer is a new parent, the brand that reads as clinical can charge six times the brand that reads as herbal, and lose nothing in volume.
I cannot measure why from listings alone, so treat this as inference rather than data: the recommendation happens in a paediatrician's room, not on Instagram. That is a channel a D2C playbook is not built for, and it is invisible in every metric we normally track.
The price spread is 51x
| Brand | ₹/100ml | Units/mo | ₹cr/yr |
|---|---|---|---|
| LuvLap | 28 | 3,000 | 0.71 |
| Baby Dove | 48 | 4,000 | 0.92 |
| Mee Mee | 64 | 1,000 | 0.31 |
| Mother Sparsh | 68 | 5,900 | 1.74 |
| … | … | … | … |
| Mustela | 500 | 1,300 | 1.24 |
| Sebamed | 502 | 25,400 | 15.77 |
| Eight Roots | 899 | 500 | 0.54 |
| Root and Soil | 1436 | 900 | 0.39 |
The cheapest brand on the shelf is not winning, and neither is the dearest. The revenue sits with brands priced ₹300 to ₹500 per 100ml that a parent has heard of from someone they trust.
Who is holding price, and who is buying volume
Median discount, not the deepest single cut, because one clearance SKU sets a maximum that describes nothing.
| Holding price | Med. disc | Cutting hardest | Med. disc |
|---|---|---|---|
| Root and Soil | 3% | LuvLap | |
| ATOGLA | 4% | Mother Sparsh | |
| B4 Nappi Cream | 4% | Baby Dove | |
| Baby Forest | 8% | Johnson's Baby | |
| Cetaphil | 10% | Figaro Baby |
Two things stand out.
Johnson's Baby is discounting at 40% and holds 1.7% of the shelf. For decades that brand was Indian baby care. Baby Dove, at 45% off, holds 0.9%. Legacy distribution and a discount are not defending these positions.
A 46% median discount is not a promotion, it is the price. The MRP exists to make it look like a saving. That is a fine strategy until somebody does it harder than you.
What this is not
Being straight about the limits, because the headline number is the kind of thing people quote.
- GMV, not revenue. What buyers pay before Amazon's commission, fulfilment and returns. No brand receives this number.
- A floor, twice over. Amazon publishes velocity in bands, so "10K+ bought" counts as exactly 10,000, and any product with no published figure counts as zero.
- The visible shelf, not every SKU. This measures what Amazon surfaces for three searches. It is deliberately not comparable with the serum figure above, which came from crawling complete brand catalogues. Both understate, differently.
- Amazon only. Baby care sells heavily through pharmacies, general trade and quick commerce. For the dermatology brands especially, the offline share is probably large, which means their real lead is bigger than this table shows.
- Ownership is hand-classified. Whether a brand is pharma, multinational or D2C is a fact about the company, not something a product page publishes.
- One shelf, one day. 17 August 2026. Every figure is reproducible from the same public pages. If you think one is wrong I would genuinely like to know which.
What I would take from it
If you are planning a baby range because you already sell skincare: the shelf you are entering is held by brands a paediatrician recommends, at ₹300 to ₹500 per 100ml, and the incumbent you would displace is not Mamaearth at 0.8%, it is Cetaphil at 21.9%.
More generally, and this is the part I got wrong: a category next door to one you win can be held by an entirely different kind of company. Adjacency is about the product. The shelf is about who the buyer trusts. Those are not the same question, and no competitor count will tell them apart.
Happy to run the same measurement on whatever category you are circling. Comment it and I will post what comes back, including when it comes back boring.